Kcnc1 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Kcnc1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KCNC1 (Potassium Voltage-Gated Channel Subfamily C Member 1) encodes the Kv3.1 potassium channel, a high-voltage activated potassium channel critical for fast-spiking neurons.
| Property | Value |
|---|---|
| Gene Symbol | KCNC1 |
| Full Name | Potassium Voltage-Gated Channel Subfamily C Member 1 |
| Chromosomal Location | 11p15.5 |
| NCBI Gene ID | 3749 |
| Ensembl ID | ENSG00000129128 |
| UniProt | P48547 |
The KCNC1 gene encodes the Kv3.1 potassium channel subunit, a member of the Shaw-like subfamily of voltage-gated potassium channels. Kv3.1 is characterized by:
Kv3.1 channels enable:
| Disease | Association Type | Key Evidence |
|---|---|---|
| Epilepsy | Causative | KCNC1 mutations cause progressive myoclonus epilepsy (EPM7) |
| Autism Spectrum Disorder | Risk Modulator | De novo mutations found in ASD patients |
| Alzheimer's Disease | Risk Modulator | Altered Kv3.1 in fast-spiking interneurons |
| Schizophrenia | Risk Modifier | Altered expression in prefrontal cortex |
KCNC1 shows selective expression:
Kv3.1 modulators are being developed:
| Compound | Type | Status | Notes |
|---|---|---|---|
| Autism compound | Enhancer | Research | Increases Kv3.1 function |
| Retigabine | Small molecule | Approved (epilepsy) | KCNQ channel opener |
Kcnc1 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Kcnc1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Rudy B, et al. Nat Rev Neurosci 2011;12:31-40. PMID:21944652
[2] Muona M, et al. Brain 2015;138:3168-3179. PMID:26614127
[3] Lau D, et al. Neuron 2000;28:573-584. PMID:11144363
[4] Kevich AG, et al. Brain Struct Funct 2020;225:1015-1032. PMID:32157555
[5] Gu Y, et al. Cell Rep 2018;24:3013-3025. PMID:30257211
[6] Hermanstyne TO, et al. J Neurophysiol 2017;117:1788-1798. PMID:28148641
[7] Beatty JA, et al. J Neurosci 2019;39:9749-9761. PMID:31570536
[8] Macica CM, et al. J Neurosci 2003;23:4893-4905. PMID:12832519
KCNC1 encodes Kv3.1, a voltage-gated potassium channel with high expression in:
The channel is critical for high-frequency action potential firing.
Kv3.1 channels support:
Kv3.1 dysfunction contributes to epilepsy:
In AD, KCNC1 alterations affect:
Channel mutations cause cerebellar ataxia:
| Strategy | Target | Status |
|---|---|---|
| Openers | Kv3.1 channels | Preclinical |
| Gene therapy | Restore expression | Experimental |
| Modulators | Channel function | Research |
Rudy B, et al. (2001). "Kv3 channels: voltage-gated K+ channels." Journal of Neuroscience 21(15): 5742-5751. ↩︎
Martina M, et al. (2003). "Kv3.1 and fast-spiking interneurons." Cerebral Cortex 13(12): 1289-1299. ↩︎
Lau D, et al. (2000). "KCNC1 mutations cause ataxia." Neuron 28(1): 233-244. ↩︎
Espinosa F, et al. (2008). "Kv3.1 channels and epilepsy." Brain Research Reviews 58(1-2): 201-212. ↩︎
MacDonald JF, et al. (2010). "Tonic Kv3 currents in neurons." Neuroscientist 16(5): 487-500. ↩︎